JP2000516343A - キャピラリー電気泳動酵素イムノアッセイ - Google Patents
キャピラリー電気泳動酵素イムノアッセイInfo
- Publication number
- JP2000516343A JP2000516343A JP10534679A JP53467998A JP2000516343A JP 2000516343 A JP2000516343 A JP 2000516343A JP 10534679 A JP10534679 A JP 10534679A JP 53467998 A JP53467998 A JP 53467998A JP 2000516343 A JP2000516343 A JP 2000516343A
- Authority
- JP
- Japan
- Prior art keywords
- reactant
- channel
- competitor
- analyte
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 155
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 155
- 238000005251 capillar electrophoresis Methods 0.000 title abstract description 48
- 238000003018 immunoassay Methods 0.000 title description 17
- 239000012491 analyte Substances 0.000 claims abstract description 150
- 238000000034 method Methods 0.000 claims abstract description 143
- 238000001962 electrophoresis Methods 0.000 claims abstract description 123
- 238000003556 assay Methods 0.000 claims abstract description 104
- 238000004458 analytical method Methods 0.000 claims abstract description 62
- 238000009739 binding Methods 0.000 claims abstract description 38
- 230000002860 competitive effect Effects 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims description 192
- 239000000376 reactant Substances 0.000 claims description 187
- 239000000758 substrate Substances 0.000 claims description 122
- 239000007924 injection Substances 0.000 claims description 47
- 238000002347 injection Methods 0.000 claims description 47
- 230000005684 electric field Effects 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 36
- 230000008569 process Effects 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 9
- -1 Ligonucleotides Proteins 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 230000000779 depleting effect Effects 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- 102000004856 Lectins Human genes 0.000 claims description 3
- 108090001090 Lectins Proteins 0.000 claims description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 3
- 101710146873 Receptor-binding protein Proteins 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 239000002523 lectin Substances 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 229920002477 rna polymer Polymers 0.000 claims description 3
- 108010038196 saccharide-binding proteins Proteins 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 64
- 238000000926 separation method Methods 0.000 abstract description 49
- 230000035945 sensitivity Effects 0.000 abstract description 24
- 230000003321 amplification Effects 0.000 abstract description 19
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 19
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 233
- 239000000523 sample Substances 0.000 description 137
- 230000037230 mobility Effects 0.000 description 70
- 241000894007 species Species 0.000 description 67
- 238000002156 mixing Methods 0.000 description 64
- 239000003153 chemical reaction reagent Substances 0.000 description 42
- 239000000126 substance Substances 0.000 description 30
- 238000011534 incubation Methods 0.000 description 26
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 25
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 25
- 102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 description 24
- 238000005370 electroosmosis Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 19
- 239000000872 buffer Substances 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 14
- 239000000654 additive Substances 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 238000012546 transfer Methods 0.000 description 11
- 230000032258 transport Effects 0.000 description 10
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 9
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
- 238000000576 coating method Methods 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 8
- 230000005611 electricity Effects 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- BTKMJKKKZATLBU-UHFFFAOYSA-N [2-(1,3-benzothiazol-2-yl)-1,3-benzothiazol-6-yl] dihydrogen phosphate Chemical compound C1=CC=C2SC(C3=NC4=CC=C(C=C4S3)OP(O)(=O)O)=NC2=C1 BTKMJKKKZATLBU-UHFFFAOYSA-N 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 239000013626 chemical specie Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000007306 turnover Effects 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 108010032595 Antibody Binding Sites Proteins 0.000 description 5
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 5
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000008364 bulk solution Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 238000001952 enzyme assay Methods 0.000 description 5
- 238000011010 flushing procedure Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 4
- 108010044467 Isoenzymes Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000005350 fused silica glass Substances 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000004452 microanalysis Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 229940035722 triiodothyronine Drugs 0.000 description 4
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 3
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 3
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000005548 Hexokinase Human genes 0.000 description 3
- 108700040460 Hexokinases Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008051 TBE buffer Substances 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 238000005515 capillary zone electrophoresis Methods 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000000536 complexating effect Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- BIRSGZKFKXLSJQ-SQOUGZDYSA-N 6-Phospho-D-gluconate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O BIRSGZKFKXLSJQ-SQOUGZDYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108010071199 Triokinase Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000009614 chemical analysis method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000012619 stoichiometric conversion Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NFBQIWJDUKFHJP-SQOUGZDYSA-N (2r,3s,4r,5r)-3,4,5,6-tetrahydroxy-2-phosphonooxyhexanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)OP(O)(O)=O NFBQIWJDUKFHJP-SQOUGZDYSA-N 0.000 description 1
- OZXIZRZFGJZWBF-UHFFFAOYSA-N 1,3,5-trimethyl-2-(2,4,6-trimethylphenoxy)benzene Chemical compound CC1=CC(C)=CC(C)=C1OC1=C(C)C=C(C)C=C1C OZXIZRZFGJZWBF-UHFFFAOYSA-N 0.000 description 1
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- 108020001657 6-phosphogluconate dehydrogenase Proteins 0.000 description 1
- 102000004567 6-phosphogluconate dehydrogenase Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 1
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 1
- 102100028709 Thyroxine-binding globulin Human genes 0.000 description 1
- 241001664469 Tibicina haematodes Species 0.000 description 1
- 102100029290 Transthyretin Human genes 0.000 description 1
- 108050000089 Transthyretin Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- VFRROHXSMXFLSN-VANKVMQKSA-N [(2s,3s,4r,5s)-2,3,4,5-tetrahydroxy-6-oxohexyl] dihydrogen phosphate Chemical compound OP(=O)(O)OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C=O VFRROHXSMXFLSN-VANKVMQKSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- VFRROHXSMXFLSN-KCDKBNATSA-N aldehydo-D-galactose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-KCDKBNATSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000012482 calibration solution Substances 0.000 description 1
- 238000001818 capillary gel electrophoresis Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000003922 charged colloid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000005831 deiodination reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000028315 developmental maturation Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 230000005520 electrodynamics Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000003366 endpoint assay Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000012994 industrial processing Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002218 isotachophoresis Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- SHOJXDKTYKFBRD-UHFFFAOYSA-N mesityl oxide Natural products CC(C)=CC(C)=O SHOJXDKTYKFBRD-UHFFFAOYSA-N 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000009834 selective interaction Effects 0.000 description 1
- 230000035938 sexual maturation Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44747—Composition of gel or of carrier mixture
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
- G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
- G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.アッセイを実施する方法であって、以下の工程を包含する、方法: (a)第1の反応物およびサンプルを、電気泳動媒体を含むチャネルに導入する 工程であって、該サンプルが、 生体認識部分(biorecognition portion)、および 第2の反応物部分、を含む、競合剤(competitor) を含み、 ここで、該第1の反応物および該第2の反応物部分は、反応して検出可能な生成 物を形成または枯渇させる(deplete)、工程; (b)該チャネルの長さに沿って、該検出可能な生成物を該チャネルに沿って移 動させるのに十分な電位をかける(impose)工程;ならびに (c)該検出可能な生成物を検出する工程。 2.以下のさらなる工程を包含する、請求項1に記載の方法: (d)前記チャネル中で形成または枯渇した前記検出可能な生成物の量を、定量 的に測定する工程。 3.請求項1に記載の方法であって、ここで、前記第1の反応物または前記第2 の反応物部分のうちの一方が、酵素を含み、かつ、該第1の反応物または該第2 の反応物部分のうちの他方が、酵素基質を含む、方法。 4.工程(a)の前に、以下のさらなる工程を包含する、請求項1に記載の方法 : (i)固定化された反応物と分析物とを溶液中で接触させる工程; (ii)該溶液に、前記競合剤を添加する工程;および (iii)該溶液のアリコートを用いる工程であって、該アリコートが、該サン プルを規定する、工程。 5.前記固定化された反応物が、固定化された抗体である、請求項4に記載の方 法。 6.前記サンプルが、免疫反応の結果である、請求項1に記載の方法。 7.前記免疫反応が、競合反応である、請求項6に記載の方法。 8.請求項1に記載の方法であって、ここで、前記サンプルが、分析物−競合剤 複合体をさらに含み、ここで、該分析物−競合剤複合体が、分析物と前記競合剤 との会合により形成される、方法。 9.請求項8に記載の方法であって、ここで、工程(b)が、前記競合剤と前記 分析物−競合剤複合体とを分離させるのに十分な電流をかける工程をさらに包含 する、方法。 10.前記分析物が荷電している、請求項8に記載の方法。 11.前記分析物−競合剤複合体が、荷電改質剤(charge modifier)を含む、 請求項8に記載の方法。 12.請求項1に記載の方法であって、ここで、前記生体認識部分が、以下から なる群から選択される、方法:抗体、抗原、酵素、ペプチド、ペプチド核酸、オ リゴヌクレオチド、デオキシリボ核酸、リボ核酸、ビオチン、およびそれらの相 補的結合複合体、レクチンおよびそれらの相補的炭水化物結合複合体、ならびに 細胞レセプター結合タンパク質およびそれらの相補的結合生成物。 13.請求項1に記載の方法であって、工程(a)で用いられる前記チャネルが 、前記サンプルを導入する前に、前記第1の反応物を含む、方法。 14.工程(c)の前に、以下のさらなる工程を含む、請求項1に記載の方法: 前記競合剤と前記第1の反応物とを、前記検出可能な生成物が形成または枯渇 するのに十分な時間にわたって接触させた後に、前記電位を除くことによって、 前記チャネルを0の電位に供する工程。 15.請求項14に記載の方法であって、前記チャネルを0の電位に供する工程 の後で、かつ工程(c)の前に、以下の工程をさらに包含する、方法: 該チャネルの長さに沿って、該検出可能な生成物を該チャネル中で移動させる のに十分な時間にわたって、該電位を再びかける(re-impose)工程。 16.請求項1に記載の方法であって、ここで、前記サンプルが、異なる生体認 識部分を含む1つ以上の競合剤を含む、方法。 17.請求項16に記載の方法であって、ここで、1つ以上の第1の反応物が、 前記チャネル内に導入される、方法。 18.請求項17に記載の方法であって、ここで、複数の検出可能な生成物が、 形成または枯渇される、方法。 19.アッセイを実行する方法であって、以下の工程を包含する、方法: (a)分析物と、生体認識部分および第2の反応部分を含む競合剤とを含む容器 内で、結合反応を実施する工程; (b)電位をかけて、サンプルを、該容器から該容器と連通しているチャネル内 に移動させる工程であって、該チャネルが、第1の反応物を含む、工程; (c)該第2の反応部分および該第1の反応物により、検出可能な生成物を形成 または枯渇させる工程;ならびに (d)該検出可能な生成物を検出する工程。 20.請求項19に記載の方法であって、以下のさらなる工程を包含する、方 法: (d)前記チャネル内で形成または枯渇した前記検出可能な生成物の量を、定量 的に測定する工程。 21.請求項19に記載の方法であって、ここで、前記第1の反応物または前記 第2の反応物部分のうちの一方が、酵素を含み、そして、該第1の反応物または 該第2の反応物部分のうちの他方が、酵素基質を含む、方法。 22.請求項19に記載の方法であって、ここで、前記生体認識部分が、以下か らなる群から選択される、方法:抗体、抗原、酵素、ペプチド、ペプチド核酸、 オリゴヌクレオチド、デオキシリボ核酸、リボ核酸、ビオチン、およびそれらの 相補的結合複合体、レクチンおよびそれらの相補的炭水化物結合複合体、ならび に細胞レセプター結合タンパク質およびそれらの相補的結合生成物。 23.請求項19に記載の方法であって、工程(a)が、固定化された反応物を さらに含む容器内で前記反応を実施する工程をさらに包含する、方法。 24.請求項23に記載の方法であって、ここで、前記固定化された反応物が、 固定化された抗体である、方法。 25.請求項19に記載の方法であって、ここで、工程(a)で用いられる前記 チャネルが、前記サンプルを導入する前に、前記第1の反応物を含む、方法。 26.請求項19に記載の方法であって、工程(c)の前に、以下のさらなる工 程を包含する、方法: 前記競合剤と前記第1の反応物とを、前記検出可能な生成物が形成または枯渇 するのに十分な時間にわたって接触させた後に、前記電位を除くことによって、 前記チャネルを0の電位に供する工程。 27.請求項26に記載の方法であって、前記チャネルを0の電位に供する工程 の後で、かつ工程(c)の前に、以下の工程さらに包含する、方法: 該チャネルの長さに沿って、該検出可能な生成物を該チャネル中で移動させる のに十分な時間にわたって、該電位を再びかける工程。 28.チャネルを備える分析装置であって、該チャネルが、以下を含む、装置: 電気泳動媒体、および 競合剤の第2の反応部分と反応させるための第1の反応物であって、検出可能 な生成物を形成または枯渇させるための生体認識部分を含む、第1の反応物。 29.請求項28に記載の装置であって、前記チャネルを横切る電位をかけるお よび中断するための電気泳動装置をさらに備える、装置。 30.請求項29に記載の装置であって、前記検出可能な生成物を検出するため の検出器をさらに備える、装置。 31.請求項30に記載の装置であって、検出された前記検出可能な生成物の量 を定量的に測定するための定量分析器(quantitator)をさらに備える、装置。 32.前記チャネルが、キャピラリーである、請求項28に記載の装置。 33.請求項29に記載の装置であって、ここで、前記競合剤と前記第1の反応 物とが、該チャネル内で間隔を空けられており、その結果、前記電気泳動装置に よって前記チャネルの長さに沿って電場を印加すると、該競合剤または該第1の 反応物が、該チャネル内で移動して、該第1の反応物を、該競合剤の前記第2の 反応部分と反応させ、前記検出可能な生成物を形成または枯渇させる、装置。 34.結合反応を実施するためのサンプル注入ゾーンとチャネルとを備える分析 装置であって、該サンプル注入ゾーンが該チャネルと連通しており、そして該チ ャネルが、以下を含む、装置: 電気泳動媒体、および 生体認識部分を含む競合剤の第2の反応部分と反応させて、検出可能な生成物 を形成または枯渇させるための、第1の反応物。 35.請求項34に記載の装置であって、前記チャネルを横切る電位をかけるお よび中断するための電気泳動装置をさらに備える、装置。 36.請求項35に記載の装置であって、前記検出可能な生成物を検出するため の検出器をさらに備える、装置。 37.請求項34に記載の装置であって、先端を備え、該先端が、前記サンプル 注入ゾーンおよび前記チャネルを備える、装置。 38.請求項37に記載の装置であって、前記先端が、複数の独立したサンプル 注入ゾーンおよびチャネルを備える、装置。 39.請求項34に記載の装置であって、前記サンプル注入ゾーンが、固定化さ れた反応物を含む、装置。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/792,933 US5958202A (en) | 1992-09-14 | 1997-01-22 | Capillary electrophoresis enzyme immunoassay |
| US08/792,933 | 1997-01-22 | ||
| PCT/US1998/001156 WO1998032010A1 (en) | 1997-01-22 | 1998-01-21 | Capillary electrophoresis enzyme immunoassay |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002337258A Division JP2003202322A (ja) | 1997-01-22 | 2002-11-20 | キャピラリー電気泳動酵素イムノアッセイ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000516343A true JP2000516343A (ja) | 2000-12-05 |
| JP3476837B2 JP3476837B2 (ja) | 2003-12-10 |
Family
ID=25158533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53467998A Expired - Fee Related JP3476837B2 (ja) | 1997-01-22 | 1998-01-21 | キャピラリー電気泳動酵素イムノアッセイ |
| JP2002337258A Withdrawn JP2003202322A (ja) | 1997-01-22 | 2002-11-20 | キャピラリー電気泳動酵素イムノアッセイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002337258A Withdrawn JP2003202322A (ja) | 1997-01-22 | 2002-11-20 | キャピラリー電気泳動酵素イムノアッセイ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US5958202A (ja) |
| EP (1) | EP0954749A1 (ja) |
| JP (2) | JP3476837B2 (ja) |
| WO (1) | WO1998032010A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009507223A (ja) * | 2005-09-02 | 2009-02-19 | 和光純薬工業株式会社 | 複合体の形成方法及び分離方法 |
| US8580097B2 (en) | 2009-04-27 | 2013-11-12 | Wako Pure Chemical Industries, Ltd. | Isotachophoresis of blood-derived samples |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1021566A4 (en) * | 1997-06-09 | 2002-06-19 | Caliper Techn Corp | DEVICE AND METHOD FOR CORRECTING VARIOUS SPEEDS IN MICROFLUIDIC SYSTEMS |
| US5965410A (en) * | 1997-09-02 | 1999-10-12 | Caliper Technologies Corp. | Electrical current for controlling fluid parameters in microchannels |
| US6174675B1 (en) * | 1997-11-25 | 2001-01-16 | Caliper Technologies Corp. | Electrical current for controlling fluid parameters in microchannels |
| JP3091176B2 (ja) * | 1998-02-18 | 2000-09-25 | 株式会社ヘレナ研究所 | 分離分析検査データ処理装置 |
| US6149787A (en) * | 1998-10-14 | 2000-11-21 | Caliper Technologies Corp. | External material accession systems and methods |
| US6514700B1 (en) * | 1999-04-30 | 2003-02-04 | Aclara Biosciences, Inc. | Nucleic acid detection using degradation of a tagged sequence |
| US6322980B1 (en) * | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
| EP1185871A4 (en) * | 1999-06-01 | 2003-01-15 | Caliper Techn Corp | MICRO-SCALE ASSAYS AND MICROFLUIDIC DEVICES FOR THE CONTROL OF TRANSPORTER, INDUCED GRADIENT AND BINDING ACTIVITIES |
| US6837977B1 (en) | 1999-06-24 | 2005-01-04 | Cetek Corporation | Capillary electrophoresis method for screening for affinity ligands using a detectable competitive ligand |
| CA2375798A1 (en) * | 1999-06-24 | 2000-12-28 | Cetek Corporation | Capillary electrophoresis method for screening for affinity ligands using a detectable competitive ligand |
| US6613211B1 (en) * | 1999-08-27 | 2003-09-02 | Aclara Biosciences, Inc. | Capillary electrokinesis based cellular assays |
| US7198702B1 (en) * | 1999-09-30 | 2007-04-03 | Wako Pure Chemical Industries, Ltd. | Method for separating substances using dielectrophoretic forces |
| US6406604B1 (en) * | 1999-11-08 | 2002-06-18 | Norberto A. Guzman | Multi-dimensional electrophoresis apparatus |
| US7329388B2 (en) * | 1999-11-08 | 2008-02-12 | Princeton Biochemicals, Inc. | Electrophoresis apparatus having staggered passage configuration |
| SE9904802D0 (sv) * | 1999-12-23 | 1999-12-23 | Amersham Pharm Biotech Ab | Microfluidic surfaces |
| US6749735B1 (en) | 2000-03-16 | 2004-06-15 | David Le Febre | Electromobility focusing controlled channel electrophoresis system |
| US7141152B2 (en) * | 2000-03-16 | 2006-11-28 | Le Febre David A | Analyte species separation system |
| US7537938B2 (en) * | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
| US7160735B2 (en) * | 2000-04-28 | 2007-01-09 | Monogram Biosciences, Inc. | Tagged microparticle compositions and methods |
| US20030207300A1 (en) * | 2000-04-28 | 2003-11-06 | Matray Tracy J. | Multiplex analytical platform using molecular tags |
| US7771929B2 (en) * | 2000-04-28 | 2010-08-10 | Monogram Biosciences, Inc. | Tag library compounds, compositions, kits and methods of use |
| US20020142618A1 (en) * | 2000-08-04 | 2002-10-03 | Caliper Technologies Corp. | Control of operation conditions within fluidic systems |
| US7033475B2 (en) * | 2000-10-25 | 2006-04-25 | Shimadzu Corporation | Electrophoretic apparatus |
| KR20020032752A (ko) * | 2000-10-27 | 2002-05-04 | 김희태 | 다중 면역 반응을 통해 여러 종류의 표적 물질을 동시에검출하는 방법 및 이를 위한 검출용 키트 |
| US6942778B1 (en) * | 2000-11-28 | 2005-09-13 | Nanogen, Inc. | Microstructure apparatus and method for separating differently charged molecules using an applied electric field |
| WO2002082083A1 (en) * | 2001-04-04 | 2002-10-17 | Wako Pure Chemical Industries, Ltd. | Electrophoresis |
| CA2445053A1 (en) | 2001-05-21 | 2002-11-28 | Aclara Biosciences, Inc. | Methods and compositions for analyzing proteins |
| US7041459B2 (en) | 2001-05-21 | 2006-05-09 | Monogram Biosciences, Inc. | Analyzing phosphorylated proteins |
| WO2002097112A2 (en) * | 2001-05-26 | 2002-12-05 | Aclara Biosciences, Inc. | Catalytic amplification of multiplexed assay signals |
| CA2451753A1 (en) * | 2001-06-20 | 2003-01-03 | Cytonome, Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
| US7179423B2 (en) * | 2001-06-20 | 2007-02-20 | Cytonome, Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
| US7211442B2 (en) * | 2001-06-20 | 2007-05-01 | Cytonome, Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
| US20030015425A1 (en) * | 2001-06-20 | 2003-01-23 | Coventor Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
| US7060171B1 (en) * | 2001-07-31 | 2006-06-13 | Caliper Life Sciences, Inc. | Methods and systems for reducing background signal in assays |
| EP1421360A1 (en) * | 2001-08-03 | 2004-05-26 | Cetek Corporation | Microscale affinity purification system |
| US6803568B2 (en) * | 2001-09-19 | 2004-10-12 | Predicant Biosciences, Inc. | Multi-channel microfluidic chip for electrospray ionization |
| US20030094369A1 (en) * | 2001-10-01 | 2003-05-22 | Brigham Young University | Method of simultaneously concentrating and separating analytes |
| US7045311B2 (en) * | 2001-10-25 | 2006-05-16 | Monogram Biosciences, Inc. | Whole cell assay systems for cell surface proteases |
| US20030111494A1 (en) * | 2001-10-26 | 2003-06-19 | Sequenom, Inc. | Method and apparatus for high-throughput sample handling process line |
| CN1166422C (zh) * | 2001-11-05 | 2004-09-15 | 北京源德生物医学工程股份有限公司 | 用于体外高能聚焦超声波治疗机的坐位架 |
| US20050053939A1 (en) * | 2001-11-09 | 2005-03-10 | Ahmed Chenna | Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents |
| US7105810B2 (en) * | 2001-12-21 | 2006-09-12 | Cornell Research Foundation, Inc. | Electrospray emitter for microfluidic channel |
| DE10211818B4 (de) * | 2002-03-16 | 2006-07-06 | peS Gesellschaft für medizinische Diagnose-Systeme mbH | Verfahren zur quantitativen Bestimmung mehrerer Analyten |
| WO2003095989A1 (en) | 2002-05-10 | 2003-11-20 | Applera Corporation | Imaging system for reduction of interstitial image regions and its related method |
| US20040229299A1 (en) * | 2002-05-21 | 2004-11-18 | Badal M. Youssouf | Intracellular complexes as biomarkers |
| US20040229293A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | Surface receptor complexes as biomarkers |
| US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| US7402397B2 (en) * | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| US7560239B2 (en) * | 2002-06-04 | 2009-07-14 | Lin-Zhi International Inc. | Homogeneous enzyme immunoassay for simultaneous detection of multiple analytes |
| GB0213979D0 (en) * | 2002-06-18 | 2002-07-31 | Sec Dep Of The Home Department | Improvements in and relating to analysis |
| US20040175765A1 (en) * | 2002-07-05 | 2004-09-09 | Sharat Singh | Cell-screening assay and composition |
| JP4443407B2 (ja) | 2002-07-25 | 2010-03-31 | アクララ バイオサイエンシーズ, インコーポレイテッド | レセプターオリゴマー形成の検出 |
| US7179357B2 (en) * | 2002-10-25 | 2007-02-20 | Beckman Coulter, Inc. | Serial sample injection in capillary electrophoresis |
| JP4005907B2 (ja) * | 2002-12-12 | 2007-11-14 | 株式会社日立ハイテクノロジーズ | キャピラリアレイ装置、その製造方法、及び電気泳動分析方法 |
| US7007710B2 (en) | 2003-04-21 | 2006-03-07 | Predicant Biosciences, Inc. | Microfluidic devices and methods |
| US7425700B2 (en) * | 2003-05-22 | 2008-09-16 | Stults John T | Systems and methods for discovery and analysis of markers |
| US20040236603A1 (en) * | 2003-05-22 | 2004-11-25 | Biospect, Inc. | System of analyzing complex mixtures of biological and other fluids to identify biological state information |
| US7402398B2 (en) * | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
| US20060194306A1 (en) * | 2003-08-25 | 2006-08-31 | Herr Amy E | System for gel electrophoretic immunoassay |
| US20060191792A1 (en) * | 2003-08-25 | 2006-08-31 | Herr Amy E | Method and apparatus for gel electrophoretic immunoassay |
| US7537807B2 (en) * | 2003-09-26 | 2009-05-26 | Cornell University | Scanned source oriented nanofiber formation |
| CA2543830A1 (en) * | 2003-10-27 | 2005-05-19 | Monogram Biosciences, Inc. | Detecting human anti-therapeutic antibodies |
| US8007724B2 (en) * | 2003-11-07 | 2011-08-30 | Princeton Biochemicals, Inc. | Electrophoresis apparatus having at least one auxiliary buffer passage |
| JP2007510935A (ja) * | 2003-11-07 | 2007-04-26 | プリンストン・バイオケミカルズ・インコーポレーテッド | 多次元電気泳動装置 |
| FR2862134B1 (fr) * | 2003-11-12 | 2007-07-27 | Sebia Sa | Analyse et typage de proteines monoclonales par electrophorese capillaire et immunodeplacement |
| US20050130319A1 (en) * | 2003-12-15 | 2005-06-16 | Xerox Corporation | Molecular binding event detection using separation channels |
| US20050244973A1 (en) * | 2004-04-29 | 2005-11-03 | Predicant Biosciences, Inc. | Biological patterns for diagnosis and treatment of cancer |
| US7407816B2 (en) * | 2004-05-07 | 2008-08-05 | Gentius, Inc | Isoelectric particles and uses thereof |
| EP1776581B1 (en) * | 2004-07-19 | 2015-05-06 | ProteinSimple | Method for protein detection |
| US20060060769A1 (en) | 2004-09-21 | 2006-03-23 | Predicant Biosciences, Inc. | Electrospray apparatus with an integrated electrode |
| US7591883B2 (en) * | 2004-09-27 | 2009-09-22 | Cornell Research Foundation, Inc. | Microfiber supported nanofiber membrane |
| EP2537657A3 (en) | 2005-08-09 | 2016-05-04 | The University of North Carolina At Chapel Hill | Methods and materials for fabricating microfluidic devices |
| WO2007056561A2 (en) * | 2005-11-09 | 2007-05-18 | Liquidia Technologies, Inc. | Medical device, materials, and methods |
| RU2327978C2 (ru) * | 2006-05-22 | 2008-06-27 | Общество с ограниченной ответственностью "Центр коллективного пользования "Аналитическая спектрометрия" | Способ идентификации объекта путем построения его характеристического электрофоретического профиля |
| WO2008091568A2 (en) | 2007-01-23 | 2008-07-31 | Dtherapeutics, Llc | Applications of scaling laws of tree structures |
| US9591994B2 (en) | 2007-01-23 | 2017-03-14 | Dtherapeutics, Llc | Systems and methods to obtain a myocardial mass index indicative of an at-risk myocardial region |
| CA2736182A1 (en) * | 2007-09-10 | 2009-03-19 | Lyzer Diagnostics, Inc. | Apparatus, compositions and methods for rapid competitive homogeneous assay |
| US7959861B2 (en) * | 2007-09-19 | 2011-06-14 | Stc.Unm | Integrated affinity microcolumns and affinity capillary electrophoresis |
| US8357277B2 (en) * | 2007-11-27 | 2013-01-22 | Laboratory Corp. of America Holdings | Enhanced method for detecting and/or quantifying an analyte in a sample |
| CA2646944A1 (en) * | 2007-11-30 | 2009-05-30 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Serum components that bind to threat agents |
| EP2352025B1 (en) * | 2008-08-11 | 2020-07-15 | Fujimori Kogyo Co., Ltd. | Blood-platelet test method |
| US9261482B1 (en) | 2010-04-16 | 2016-02-16 | Applied Research Associates, Inc. | Gradient elution moving boundary electrophoresis for use with complex samples and detection of toxins |
| CN101963614A (zh) * | 2010-09-03 | 2011-02-02 | 青岛科技大学 | 毛细管电泳电化学酶联免疫分析检测雪卡毒素的方法 |
| US10067088B2 (en) | 2014-06-20 | 2018-09-04 | Applied Research Associates, Inc. | Gradient elution isotachophoretic apparatus for separating, purifying, concentrating, quantifying, and/or extracting charged analytes and methods thereof |
| CA3120895C (en) | 2018-12-20 | 2024-07-02 | Sergey N. Krylov | BINDER SELECTION USING CAPILLARY ELECTROPHORESIS |
| CN117169534A (zh) | 2019-08-05 | 2023-12-05 | 禧尔公司 | 用于样品制备、数据生成和蛋白质冠分析的系统和方法 |
| US12332179B2 (en) * | 2020-07-10 | 2025-06-17 | Thomas G. Mason | Colliding and reacting molecules and colloids electrophoretically |
| CN116878985A (zh) * | 2023-07-12 | 2023-10-13 | 北京师范大学 | 一种水溶液中镉离子和铅离子的检测方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4288425A (en) * | 1979-01-31 | 1981-09-08 | Technicon Instruments Corporation | Method and apparatuses for electrophoretic immunoassay |
| US4307070A (en) * | 1979-01-31 | 1981-12-22 | Technicon Instruments Corporation | Methods and apparatuses for performing immunoassays |
| US4181589A (en) * | 1979-03-06 | 1980-01-01 | Nasa | Method for separating biological cells |
| US4312727A (en) * | 1979-03-23 | 1982-01-26 | The Cleveland Clinic Foundation | Glyoxal agarose and zonal immobilization of proteins therewith |
| US4849353A (en) * | 1980-09-30 | 1989-07-18 | Cornell Research Foundation, Inc. | Immunocapture of enzyme inhibitor, enzyme complexes and uses thereof |
| US4753875A (en) * | 1981-11-02 | 1988-06-28 | Ryan James W | Method for assaying proteases with tagged proteinaceous inhibitors |
| JPS61272661A (ja) | 1985-05-29 | 1986-12-02 | Hitachi Ltd | イムノアツセイ法 |
| US4865706A (en) * | 1986-10-21 | 1989-09-12 | Northeastern University | High performance microcapillary gel electrophoresis |
| US4865707A (en) * | 1986-10-21 | 1989-09-12 | Northeastern University | Capillary gel electrophoresis columns |
| US5084150A (en) * | 1987-03-24 | 1992-01-28 | Northeastern University | Selective high performance electrokinetic separations employing the surface of moving charged colloidal particles |
| JP2564540B2 (ja) * | 1987-04-01 | 1996-12-18 | 株式会社日立製作所 | 免疫分析方法 |
| US5045172A (en) * | 1987-11-25 | 1991-09-03 | Princeton Biochemicals, Inc. | Capillary electrophoresis apparatus |
| US5061361A (en) * | 1989-03-06 | 1991-10-29 | Hewlett-Packard Company | Capillary zone electrophoresis cell system |
| WO1991006850A1 (en) * | 1989-11-06 | 1991-05-16 | Massachusetts Institute Of Technology | Affinity co-electrophoresis |
| GB2244135B (en) * | 1990-05-04 | 1994-07-13 | Gen Electric Co Plc | Sensor devices |
| US5122248A (en) * | 1990-05-18 | 1992-06-16 | Northeastern University | Pulsed field capillary electrophoresis |
| US5089099A (en) * | 1990-11-30 | 1992-02-18 | Varian Associates, Inc. | Field amplified polarity switching sample injection in capillary zone electrophoresis |
| US5116471A (en) * | 1991-10-04 | 1992-05-26 | Varian Associates, Inc. | System and method for improving sample concentration in capillary electrophoresis |
| US5145567A (en) * | 1991-11-14 | 1992-09-08 | Beckman Instruments, Inc. | Capillary zone electrophoretic analysis of isoenzymes |
| US5264095A (en) * | 1991-11-14 | 1993-11-23 | Beckman Instruments, Inc. | Capillary zone electrophoretic analysis of isoenzymes |
| US5137609A (en) * | 1992-01-31 | 1992-08-11 | Biometric Imaging Inc. | Differential separation assay |
| JPH08501392A (ja) * | 1992-09-14 | 1996-02-13 | パーデュー リサーチ ファウンデーション | 電気泳動法による化学分析 |
| US5571680A (en) * | 1994-01-21 | 1996-11-05 | Beckman Instruments, Inc. | Homogeneous immunoassays and enzyme based assays of analytes using capillary electrophoresis |
| US5536382A (en) * | 1994-05-23 | 1996-07-16 | Advanced Molecular Systems, Inc. | Capillary electrophoresis assay method useful for the determination of constituents of a clinical sample |
| US5500071A (en) * | 1994-10-19 | 1996-03-19 | Hewlett-Packard Company | Miniaturized planar columns in novel support media for liquid phase analysis |
| US5645702A (en) * | 1995-06-07 | 1997-07-08 | Hewlett-Packard Company | Low voltage miniaturized column analytical apparatus and method |
| US5646048A (en) * | 1995-07-24 | 1997-07-08 | Hewlett-Packard Company | Microcolumnar analytical apparatus with microcolumnar flow gating interface and method of using the apparatus |
| US5650846A (en) * | 1995-11-21 | 1997-07-22 | Hewlett-Packard Company | Microcolumnar analytical system with optical fiber sensor |
| EP0862708A4 (en) * | 1995-12-18 | 1998-11-25 | Armand P Neukermans | MICROFLUIDIC VALVE AND INTEGRATED MICROFLUIDIC SYSTEM |
-
1997
- 1997-01-22 US US08/792,933 patent/US5958202A/en not_active Expired - Lifetime
-
1998
- 1998-01-21 EP EP98902668A patent/EP0954749A1/en not_active Withdrawn
- 1998-01-21 JP JP53467998A patent/JP3476837B2/ja not_active Expired - Fee Related
- 1998-01-21 WO PCT/US1998/001156 patent/WO1998032010A1/en not_active Ceased
-
2002
- 2002-11-20 JP JP2002337258A patent/JP2003202322A/ja not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009507223A (ja) * | 2005-09-02 | 2009-02-19 | 和光純薬工業株式会社 | 複合体の形成方法及び分離方法 |
| US8580097B2 (en) | 2009-04-27 | 2013-11-12 | Wako Pure Chemical Industries, Ltd. | Isotachophoresis of blood-derived samples |
| US8795499B2 (en) | 2009-04-27 | 2014-08-05 | Wako Pure Chemical Industries, Ltd. | Isotachophoresis of blood-derived samples |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0954749A1 (en) | 1999-11-10 |
| WO1998032010A1 (en) | 1998-07-23 |
| JP3476837B2 (ja) | 2003-12-10 |
| US5958202A (en) | 1999-09-28 |
| JP2003202322A (ja) | 2003-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3476837B2 (ja) | キャピラリー電気泳動酵素イムノアッセイ | |
| EP0660926B1 (en) | Electrophoretically mediated chemical analysis | |
| US5948231A (en) | Compositions, methods and apparatus for ultrafast electroseparation analysis | |
| Vandaveer IV et al. | Recent developments in electrochemical detection for microchip capillary electrophoresis | |
| Uchiyama et al. | Detection method for microchip separations | |
| Sato et al. | Microchip‐based immunoassay system with branching multichannels for simultaneous determination of interferon‐γ | |
| Wang et al. | Voltammetry on microfluidic chip platforms | |
| Ronkainen-Matsuno et al. | Electrochemical immunoassay moving into the fast lane | |
| Hashimoto et al. | Microchip capillary electrophoresis using on-line chemiluminescence detection | |
| Wang et al. | Microchip‐based amperometric immunoassays using redox tracers | |
| JP2006516721A (ja) | 多孔質層上に試薬を含む複層化された電気化学系微小流体センサー | |
| JP2009533658A (ja) | 最適化電流測定検出を用いる小型バイオセンサー | |
| Morier et al. | Gravity‐induced convective flow in microfluidic systems: Electrochemical characterization and application to enzyme‐linked immunosorbent assay tests | |
| Guihen | Recent advances in miniaturization—The role of microchip electrophoresis in clinical analysis | |
| Guijt et al. | Use of bioaffinity interactions in electrokinetically controlled assays on microfabricated devices | |
| Xu et al. | Parallel analysis with optically gated sample introduction on a multichannel microchip | |
| Sabbagh et al. | Enhancing commercially available immunoassays through a customized electrokinetic biomolecular preconcentration device | |
| Murakami et al. | On-chip capillary electrophoresis for alkaline phosphatase testing | |
| Vlčková et al. | Microchip affinity capillary electrophoresis: applications and recent advances | |
| Thormann | Drug monitoring by capillary electrophoresis | |
| Fogarty et al. | Microchip capillary electrophoresis: application to peptide analysis | |
| Zhuang et al. | Microchip‐based capillary electrophoresis for determination of lactate dehydrogenase isoenzymes | |
| Tsukagoshi et al. | Development of an immune microanalysis system by use of peroxyoxalate chemiluminescence detection | |
| Fung | Microfluidic Chip-Capillary Electrophoresis: Expanding the Scope of Application for On-Site Analysis of Difficult Samples | |
| McCornack et al. | Engineering Avidin-Functionalized Gold Nanoparticles for LIGMA: A Cationic Isotachophoresis-Driven Lateral Flow Assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080926 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090926 Year of fee payment: 6 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090926 Year of fee payment: 6 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100926 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110926 Year of fee payment: 8 |
|
| LAPS | Cancellation because of no payment of annual fees |